Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffany Roe

Nurse Practitioner, Family Shreveport, LA Nurse Practitioner

NPI 1548661440 CMS profile 10735257

820 Jordan St, Suite 201, Shreveport, LA 71101

Open in the dashboard

General payments

$97,029

1,118 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Roe of Shreveport, LA is reported in the CMS Open Payments database as having received $97,029 across 1,118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,537 192
2024 General $16,410 204
2023 General $21,759 229
2022 General $30,944 244
2021 General $18,379 249

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Roe
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Tiffany Roe were reported at $9,537. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Tiffany Roe Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $18,379 $124 $35–$379 $132
2022 $30,944 $141 $44–$430 $149
2023 $21,759 $154 $49–$476 $160
2024 $16,410 $165 $51–$504 $164
2025 $9,537 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $40,768 127 payments
  2. AbbVie, Inc. $21,885 207 payments
  3. Amgen Inc. $14,860 290 payments
  4. Novartis Pharmaceuticals Corporation $4,239 82 payments
  5. Janssen Biotech, Inc. $3,063 73 payments
  6. Mallinckrodt Hospital Products Inc. $2,072 36 payments
  7. UCB, Inc. $1,824 88 payments
  8. Sobi, Inc $1,730 4 payments
  9. Eli Lilly and Company $1,234 2 payments
  10. E.R. Squibb & Sons, L.L.C. $1,212 19 payments
  11. Other $4,143 190 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,113 77 payments
  2. Food and Beverage $22,622 999 payments
  3. Consulting Fee $11,468 9 payments
  4. Travel and Lodging $6,709 28 payments
  5. Education $118 5 payments
Products named General payments · program years 2021–2025
  1. TALTZ $37,478 113 payments
  2. RINVOQ $20,961 176 payments
  3. Enbrel Inflammation $11,035 100 payments
  4. OLUMIANT $10,951 35 payments
  5. TREMFYA $2,515 39 payments
  6. COSENTYX $2,214 54 payments
  7. ACTHAR $2,072 36 payments
  8. Otezla $1,844 104 payments
  9. Cimzia $1,237 66 payments
  10. Enbrel Inflammation $1,227 85 payments
  11. Other $11,102 536 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,382

Median for Nurse Practitioner: 389

Drug cost

$46,044

Median for Nurse Practitioner: $21,885

Branded share of claims

39.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methotrexate Methotrexate Sodium Brand 533 $14,815
Hydroxychloroquine Sulfate Generic 298 $12,839
Leflunomide Generic 98 $7,836
Celecoxib Generic 100 $3,140
Leucovorin Calcium Generic 50 $2,128
Allopurinol Generic 135 $1,601
Mycophenolate Mofetil Generic 21 $1,315
Diclofenac Sodium Generic 11 $758
Sulfasalazine Generic 31 $637
Folic Acid Generic 48 $545

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$15,794

Of which drugs: $180

Medicare patients

107

Average age 75

Services billed

457

83 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 58%
Chronic kidney disease 40%
Ischemic heart disease 30%
Diabetes 27%
Depression 24%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 12 24 $133

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TALTZ
$8,352 — —
TREMFYA
$1,862 — —
COSENTYX
$1,514 — —
Enbrel
$410 — —
RINVOQ
$332 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

1,118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record